Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
We confirmed that combination treatment of ICI and TT is associated with the amplified risk of hepatitis, which is partly due to the interaction between ICI and TT, and the KRAS-targeted drugs may harbor the highest potential for hepatitis induction among TT drugs when combined with ICI. Besides, the combination treatment of ICI- and KRAS-targeted drugs also increases the incidence of colitis, pulmonary embolism and dehydration.
Authors
- Zixiang Zhou (ORCID: https://orcid.org/0009-0008-5290-9263)
- Hanping Wang (ORCID: https://orcid.org/0000-0003-3540-2280)
- Xiangqi Chen (ORCID: https://orcid.org/0000-0003-3367-6261)
- Bing Tian (ORCID: https://orcid.org/0000-0003-2446-4363)
- Haitao Zhao (ORCID: https://orcid.org/0000-0002-3444-8044)
- Nan Zhang (ORCID: https://orcid.org/0000-0002-3447-2212)
- Zhaohui Li (ORCID: https://orcid.org/0000-0003-4009-4374)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1007/s00262-024-03858-4
- Citations
- 7
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 2.45
Funders
- Peking Union Medical College Hospital